Briefing
Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
ctDNA-positive rate was 57% (260/460) at baseline and fell to 22% (94/422) after neoadjuvant treatment, pre-cystectomy. Clearance from baseline to pre-cystectomy was 41% with durvalumab plus NAC vs 31% with NAC alone. Pre-cystectomy ctDNA-positive status was associated with non-pCR in 97% (86/89). Event-free survival benefit of perioperative durvalumab was observed in both baseline ctDNA-positive and ctDNA-negative groups. Post-cystectomy ctDNA-positive rate was 9% (31/345).
- n: 462 biomarker-evaluable of 1063 randomized (237 durvalumab arm, 225 control)
- Assay: Signatera (named in the abstract)